Physician profile
James C Wall, JR.
NPI 1467538652
$1,561.53
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,114 · 2020: $264 · 2021: $183.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $398.14 | 2019-2021 | |
| Allergan, INC. | $265.09 | 2019-2020 | |
| Astrazeneca Pharmaceuticals Lp | $198.37 | 2019 | |
| Pfizer INC. | $107.76 | 2020-2021 | |
| Novo Nordisk INC | $102.69 | 2019 | |
| Esperion Therapeutics, INC. | $101.22 | 2021 | |
| Abbvie INC. | $93.58 | 2019 | |
| Corcept Therapeutics | $85.15 | 2019 | |
| Lilly USA, LLC | $71.57 | 2019 | |
| Scilex Pharmaceuticals INC. | $41.06 | 2019 | |
| Merck Sharp & Dohme LLC | $37.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $30.90 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.94 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.